Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Ziihera (zanidatamab-hrii)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BeiGene, Jazz, Zymeworks

Drug class:

HER2 inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

mobocertinib (12)

trastuzumab-dttb (11)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HER-2 expression	Biliary Tract Cancer	HER-2 expression	Biliary Tract Cancer	zanidatamab-hrii Sensitive: B - Late Trials zanidatamab-hrii Sensitive : B	zanidatamab-hrii Sensitive: B - Late Trials zanidatamab-hrii Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	zanidatamab-hrii Sensitive: C2 – Inclusion Criteria zanidatamab-hrii Sensitive : C2	zanidatamab-hrii Sensitive: C2 – Inclusion Criteria zanidatamab-hrii Sensitive : C2
HER-2 amplification	Biliary Tract Cancer	HER-2 amplification	Biliary Tract Cancer	zanidatamab-hrii Sensitive: C2 – Inclusion Criteria zanidatamab-hrii Sensitive : C2	zanidatamab-hrii Sensitive: C2 – Inclusion Criteria zanidatamab-hrii Sensitive : C2
HER-2 overexpression	Biliary Tract Cancer	HER-2 overexpression	Biliary Tract Cancer	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3
HER-2 expression	Gastroesophageal Cancer	HER-2 expression	Gastroesophageal Cancer	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3
HER-2 overexpression	Gastroesophageal Cancer	HER-2 overexpression	Gastroesophageal Cancer	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3	zanidatamab-hrii Sensitive: C3 – Early Trials zanidatamab-hrii Sensitive : C3
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	tislelizumab-jsgr + zanidatamab-hrii Sensitive: C3 – Early Trials tislelizumab-jsgr + zanidatamab-hrii Sensitive : C3	tislelizumab-jsgr + zanidatamab-hrii Sensitive: C3 – Early Trials tislelizumab-jsgr + zanidatamab-hrii Sensitive : C3
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	tislelizumab-jsgr + zanidatamab-hrii Sensitive: C3 – Early Trials tislelizumab-jsgr + zanidatamab-hrii Sensitive : C3	tislelizumab-jsgr + zanidatamab-hrii Sensitive: C3 – Early Trials tislelizumab-jsgr + zanidatamab-hrii Sensitive : C3
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	palbociclib + zanidatamab-hrii Sensitive: C3 – Early Trials palbociclib + zanidatamab-hrii Sensitive : C3	palbociclib + zanidatamab-hrii Sensitive: C3 – Early Trials palbociclib + zanidatamab-hrii Sensitive : C3